Cargando…

Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis

Robust population pharmacokinetic (PK) data for fluconazole are scarce. The variability of fluconazole penetration into the central nervous system (CNS) is not known. A fluconazole PK study was conducted in 43 patients receiving oral fluconazole (usually 800 mg every 24 h [q24h]) in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stott, Katharine E., Beardsley, Justin, Kolamunnage-Dona, Ruwanthi, Castelazo, Anahi Santoyo, Kibengo, Freddie Mukasa, Mai, Nguyen Thi Hoang, Tùng, Nguyễn Lê Nhu’, Cuc, Ngo Thi Kim, Day, Jeremy, Hope, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125572/ https://www.ncbi.nlm.nih.gov/pubmed/29914943 http://dx.doi.org/10.1128/AAC.00885-18

Ejemplares similares

Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018)

An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2021)

A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2019)

Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance
por: Hope, William, et al.
Publicado: (2019)

Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis
por: Mpoza, Edward, et al.
Publicado: (2017)

Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis
por: Kitonsa, Jonathan, et al.
Publicado: (2021)

Do Intracerebral Cytokine Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency Virus–associated Cryptococcal Meningitis?
por: Beardsley, Justin, et al.
Publicado: (2019)

Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis
por: Stone, Neil R.H., et al.
Publicado: (2019)

Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients
por: Nasri, Hashem, et al.
Publicado: (2016)

High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
por: Zhao, Hua-Zhen, et al.
Publicado: (2018)

Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda
por: Kitonsa, Jonathan, et al.
Publicado: (2020)

Symptomatic Cryptococcal Meningitis with Negative Serum and Cerebrospinal Fluid Cryptococcal Antigen Tests
por: Nanfuka, Vivien, et al.
Publicado: (2021)

88462 Fluconazole distribution in CNS and gynecological tissues in HIV-related cryptococcal meningitis decedents
por: Nicol, Melanie R., et al.
Publicado: (2021)

B Cell Compartmentalization in Blood and Cerebrospinal Fluid of HIV-Infected Ugandans with Cryptococcal Meningitis
por: Okurut, Samuel, et al.
Publicado: (2020)

CryptoDex: A randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial
por: Day, Jeremy, et al.
Publicado: (2014)

Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis
por: Shiri, Tinevimbo, et al.
Publicado: (2020)

Kinetics of HIV-1 in cerebrospinal fluid and plasma in cryptococcal meningitis
por: Cecchini, Diego M., et al.
Publicado: (2012)

Cryptococcal meningitis associated with increased adenosine deaminase in the cerebrospinal fluid
por: Tanaka, Yuji, et al.
Publicado: (2016)

Nanopore sequencing of cerebrospinal fluid of three patients with cryptococcal meningitis
por: Jin, Ke, et al.
Publicado: (2022)

Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2022)

Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei
por: Le, Thuy, et al.
Publicado: (2019)

Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda
por: Kitonsa, Jonathan, et al.
Publicado: (2019)

Flow Cytometry To Assess Cerebrospinal Fluid Fungal Burden in Cryptococcal Meningitis
por: Scriven, James E., et al.
Publicado: (2016)

Liquid-Based Cytology of the Cerebrospinal Fluid in a Case of Cryptococcal Meningitis
por: Choi, Jiwoon, et al.
Publicado: (2018)

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
por: Schaars, CF, et al.
Publicado: (2006)

Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis
por: Molloy, Síle F., et al.
Publicado: (2018)

Real-time PCR for detection of Streptococcus suis serotype 2 in cerebrospinal fluid of human patients with meningitis
por: Nga, Tran Vu Thieu, et al.
Publicado: (2011)

Antifungal Susceptibility Does Not Correlate With Fungal Clearance or Survival in AIDS-Associated Cryptococcal Meningitis
por: O’Connor, Lucy, et al.
Publicado: (2020)

Sterile Cerebrospinal Fluid Culture at Cryptococcal Meningitis Diagnosis Is Associated with High Mortality
por: Skipper, Caleb P, et al.
Publicado: (2022)

Induction therapy with high‐dose fluconazole plus flucytosine for human immunodeficiency virus‐uninfected cryptococcal meningitis patients: Feasible or not?
por: Zhao, Hua‐Zhen, et al.
Publicado: (2022)

Evaluating statistical characteristics of biomarker-guided trial designs
por: Antoniou, Miranta, et al.
Publicado: (2015)

Sample size formula for joint modelling of longitudinal and time-to-event data in clinical trials
por: Powney, Matthew, et al.
Publicado: (2013)

Adjusting for informative missing outcome data in clinical trials with longitudinal study designs
por: Kolamunnage-Dona, Ruwanthi, et al.
Publicado: (2013)

Divergent Neuroimmune Signatures in the Cerebrospinal Fluid Predict Differential Gender-Specific Survival Among Patients With HIV-Associated Cryptococcal Meningitis
por: Okurut, Samuel, et al.
Publicado: (2023)

Analysis of cerebrospinal fluid protein concentrations of patients with cryptococcal meningitis treated with antifungal agents
por: Huang, Liang, et al.
Publicado: (2015)

Increased activity of the complement system in cerebrospinal fluid of the patients with Non-HIV Cryptococcal meningitis
por: Shen, Lei, et al.
Publicado: (2017)

Metataxonomics of Internal Transcribed Spacer amplicons in cerebrospinal fluid for diagnosing and genotyping of cryptococcal meningitis
por: Zhu, Ji-Ting, et al.
Publicado: (2019)

A Prospective Study of Mortality from Cryptococcal Meningitis following Treatment Induction with 1200mg Oral Fluconazole in Blantyre, Malawi
por: Gaskell, Katherine M., et al.
Publicado: (2014)

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2016)

Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study
por: Kolamunnage-Dona, Ruwanthi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4qu7pri0r27hne93uf6u76v68r